Direkt zum Inhalt
Merck

SML3083

Sigma-Aldrich

Palovarotene

≥98% (HPLC)

Synonym(e):

(E)-4-(2-(3-((1H-Pyrazol-1-yl)methyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid, 4-[(1E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]ethenyl]benzoic acid, 4-[(E)-2-(5,5,8,8-Tetramethyl-3-pyrzol-1-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid, R 667, R-667, R667, RG 667, RG-667, RG667, RO 3300074, RO-3300074, RO3300074

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C27H30N2O2
CAS-Nummer:
Molekulargewicht:
414.54
MDL-Nummer:
UNSPSC-Code:
12352200
NACRES:
NA.77

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

CC1(C2=CC(CN3C=CC=N3)=C(/C=C/C4=CC=C(C=C4)C(O)=O)C=C2C(C)(CC1)C)C

InChI

1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+

InChIKey

YTFHCXIPDIHOIA-DHZHZOJOSA-N

Biochem./physiol. Wirkung

Palovarotene is an orally active, selective retinoic acid receptor gamma (RARγ) agonist that reduces heterotopic ossification (HO) in cultures (15-300 nM) and in murine and rat fibrodysplasia ossificans progressiva (FOP) models in vivo (1 mg/kg rat, 0.27-2.49 mg/kg mouse or 15-100 μg/mouse via daily p.o.).

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Sayantani Sinha et al.
Bone, 90, 59-68 (2016-02-20)
Heterotopic ossification (HO) consists of ectopic cartilage and bone formation following severe trauma or invasive surgeries, and a genetic form of it characterizes patients with Fibrodysplasia Ossificans Progressiva (FOP). Recent mouse studies showed that HO was significantly inhibited by systemic
Benjamin M Wheatley et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 36(4), 1135-1144 (2017-09-30)
Heterotopic ossification (HO) develops in the extremities of wounded service members and is common in the setting of high-energy penetrating injuries and blast-related amputations. No safe and effective prophylaxis modality has been identified for this patient population. Palovarotene has been
Sonia A Garcia et al.
International journal of molecular sciences, 21(8) (2020-04-17)
Osteochondromas are cartilage-capped growths located proximate to the physis that can cause skeletal deformities, pain, limited motion, and neurovascular impingement. Previous studies have demonstrated retinoic acid receptor gamma (RARγ) agonists to inhibit ectopic endochondral ossification, therefore we hypothesize that RARγ

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.